AVITA Medical, Inc. (RCEL)

NASDAQ: RCEL · IEX Real-Time Price · USD
17.58
+0.10 (0.57%)
At close: Feb 20, 2024, 4:00 PM
17.41
-0.17 (-0.97%)
After-hours: Feb 20, 2024, 6:14 PM EST
0.57%
Market Cap 436.74M
Revenue (ttm) 47.80M
Net Income (ttm) -33.67M
Shares Out 24.84M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 169,190
Open 17.20
Previous Close 17.48
Day's Range 16.81 - 17.95
52-Week Range 8.88 - 21.70
Beta 1.39
Analysts Strong Buy
Price Target 25.40 (+44.48%)
Earnings Date Feb 22, 2024

About RCEL

AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and del... [Read more]

Industry Medical Devices
Sector Healthcare
CEO James M. Corbett
Employees 126
Stock Exchange NASDAQ
Ticker Symbol RCEL
Full Company Profile

Financial Performance

In 2022, AVITA Medical's revenue was 37.64 million, an increase of 8.73% compared to the previous year's 34.62 million. Losses were -26.67 million, 6.06% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price forecast is $25.4, which is an increase of 44.48% from the latest price.

Price Target
$25.4
(44.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results

VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell...

19 days ago - GlobeNewsWire

AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific

VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and...

5 weeks ago - GlobeNewsWire

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and...

5 weeks ago - GlobeNewsWire

AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell...

6 weeks ago - GlobeNewsWire

AVITA Medical to Host Investor Webinar Briefing

VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...

2 months ago - GlobeNewsWire

AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference

VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...

3 months ago - GlobeNewsWire

AVITA Medical Updates Full Year 2023 Guidance

VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...

3 months ago - GlobeNewsWire

AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...

3 months ago - GlobeNewsWire

AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe

AVITA Medical announced it has entered into a distribution agreement with PolyMedics Innovations, to strategically expand its global presence to Europe.

3 months ago - GlobeNewsWire

AVITA Medical to Announce Third Quarter 2023 Financial Results

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device...

4 months ago - GlobeNewsWire

AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma

VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...

5 months ago - GlobeNewsWire

AVITA Medical to Present at the Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...

5 months ago - GlobeNewsWire

AVITA Medical to Participate in Upcoming Investor Conferences

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...

5 months ago - GlobeNewsWire

AVITA Medical Reports Second Quarter Financial Results

VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...

6 months ago - GlobeNewsWire

AVITA Medical Submits FDA PMA Supplement for RECELL GO

VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device...

8 months ago - GlobeNewsWire

AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

8 months ago - GlobeNewsWire

AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

8 months ago - GlobeNewsWire

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

9 months ago - GlobeNewsWire

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance

VALENCIA, Calif. and MELBOURNE, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and co...

10 months ago - GlobeNewsWire

AVITA Medical to Announce First Quarter 2023 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

10 months ago - GlobeNewsWire

AVITA Medical Announces Update to Automation Device

VALENCIA, Calif. and MELBOURNE, Australia, April 13, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

11 months ago - GlobeNewsWire

AVITA Medical Appoints New Non-Executive Member to the Board of Directors

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

11 months ago - GlobeNewsWire

AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference

VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

1 year ago - GlobeNewsWire

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and c...

1 year ago - GlobeNewsWire

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

1 year ago - GlobeNewsWire